In this mechanism, DEPTOR overexpression leads to inhibition of MTOC1 and activation of AKT pathway expression [71, 72, 75–77], while DEPTOR was found to be a tumor suppressor in pancreatic cancer [78], ESCC [79], lung cancer [80], triple-negative breast cancer [72], and B-ALL [76]. Here, DEPTOR is linked to triple-negative breast carcinoma.